Authors must include an accompanying 'Submission Letter' addressed to the Editor, with the following information:
Title of
the manuscript
Contact details on the title page of their submitted manuscripts: name; full postal address; Fax; Tel; e-mail.A
paragraph that states that the work has not been previously published
The names and contact details of 3 potential referees
Manuscripts should be written in English: only light correction of English style and language will be carried out during production.
Should more extensive changes be necessary, the manuscripts will be returned to the authors for retyping. Submission of a paper
in clear, grammatical English will, therefore, shorten publication time considerably. Language Polishing: For authors who require
information about language editing and copyediting services pre- and post-submission please visit http://www.elsevier.com/ wps/find/authorshome.authors/languagepolishing
or contact authorsupport@elsevier.com for more information. Please note Elsevier neither endorses nor takes responsibility for any products,
goods or services offered by outside vendors through our services or in any advertising.
1. Conflict of interest
Environmental
Toxicology and Pharmacology requires full disclosure of all potential conflicts of interest. At the end of the manuscript text (and
in the cover letter of the manuscript), under a subheading "Conflict of Interest statement", all authors must disclose any financial
and personal relationships with other people or organisations that could inappropriately influence (bias) their work. If there are no
conflicts of interest, the authors should state, "The authors declare that there are no conflicts of interest." Signed copies of the Environmental Toxicology and Pharmacology Conflict of Interest policy form are required upon submission. The Conflict of Interest
policy form can be downloaded here. In order to minimize delays,
we strongly advise that the signed copies of these statements are prepared before you submit your manuscript.
2. On-line submission
Authors should upload their article as a Microsoft1® (MS) Word®, WordPerfect®, PostScript or Adobe® Acrobat® PDF
document via the EES website http://ees.elsevier.com/etap, where you will also find a detailed description on its use. The system generates
an Adobe Acrobat PDF version of the article which is used for the reviewing process. It is crucial that all graphical and tabular elements
be placed within the text, so that the file is suitable for reviewing. Authors, Reviewers and Editors send and receive all correspondence
by e-mail and no paper correspondence is necessary.
Note: compuscripts submitted are converted into PDF for the review process but
may need to be edited after acceptance to follow journal standards. For this an ''editable'' file format is necessary. See the section
on ''Electronic format requirements for accepted articles'' and the further general instructions on how to prepare your article below.
3. Full length manuscripts
(a) The manuscript should be arranged as follows. First page: title (not exceeding 85 characters
including
spaces between words); surname(s) of author(s), preceded by one name spelled out in full; name and address of the establishment
where the work was done; name, full postal address, telephone and telefax numbers of author to whom proofs and other correspondence should
be sent. Next page (2): abstract and keywords (indexing terms: normally 3-6 items); Pages 3 to end: 1. Introduction; 2. Materials and
methods; 3. Results; 4. Discussion; Acknowledgements; References; figure legends and figures; tables. Both sections and their subdivisions
should be numbered (2.1., 2.2., 2.3. etc).
(b) Abstract and keywords: and abstract not exceeding 150 words and stating what was done,
what was found, and what was concluded should be typed on a separate sheet. Below the abstract, type 3-6 keywords or short phrases suitable
for indexing. These terms will be printed at the end of the abstract. If possible. keywords should be selected from Index Medicus
or Excerpta Medica Index. First category key-words (e.g. Hyperphagia; G-Strophantidin; Fiber shortening) will all be listed
and cross-indexed. Second category keywords (e.g. Rat, Cold, Metabolite) will only be listed under the index entry for the first category
keywords. If the editors feel that keywords should be adjusted to the standards of the journal this will be done without consultation
of the author(s).
(c) Standard nomenclature should be used throughout. Avoid unnecessary abbreviations and symbols (see extensive
'Instructions to authors' (Vol. 1, No. 1, p. vii). Words at the end of a line should not be divided. Use of hyphens, capital letters.
numbers written or spelled out (e.g. 8 or eight) should be consistent throughout the manuscript.
(d) Legends of illustrations and
footnotes should be typed on separate sheets, lines double spaced. Footnotes, to be numbered consecutively in superscript throughout
the text, should be used as little as possible.
(e) Drugs: generic names should be used. Trade names may be mentioned in parentheses
the first time the name of the drug appears in the text. The form of the drug used should be indicated.
4. Short communications
should be prepared as described under 2, except for the following:
(a) The average length of a short communication should not
exceed 4 pages in print (approx. 2000-2300 words, including abstract, captions and references). A maximum of 2 illustrations (figures
or tables) is allowed. (b) An abstract of not more that 100 words should be provided and 3-6 keywords should be listed immediately
below the abstract.
5. Reviews
The organization and subdivision of review articles can be arranged at the author's discretion.
Tables, figures and references are to be arranged in the same way as research articles in the journal. Please contact the Editor before
submitting an article for this section.
6. Mini-reviews
(a) The total length of a mini-review should be about 30 double-spaced
typewritten pages, including references, tables and figures.
(b) A brief introduction to the subjects, comprising not more than 500
words, in which reference is made to recent key articles or reviews on the topic should be given.
(c) Conclusions should be summarized
in 500-1000 words at the end of this article. They should be preferentially outlined in a flow diagram or a graph.
(d) A maximum
of 40 references may be used.
7. Assessments
The format of an assessment will be decided upon in consultation with the
editors.
8. Letters to the editors
The total length of a letter should not exceed one page. Please name three potential
reviewes making sure to include their name, affiliation and email address.
9. Acknowledgements
All sources of funding supporting
the work are to be declared. Authors are to disclose all ?nancial relationships with any persons or organisations that could be perceived
to bias the work described in the manuscript. These acknowledgements should be placed after the text and before the references, under
the heading ''Acknowledgements''. In submitting the article for consideration for publication, the author(s) attest that all potential
con?icts of interest have been disclosed and addressed in the manuscript.
10. References
References in the text to literature
cited should be given by the name of the author(s), followed by the year of publication in parentheses, e.g.: Seegal and Sham (1992)
or (Safe, 1986; Pluim et al., 1993; Ahlborg et al., 1994, 1995a,b).For three or more authors the name of the first author followed by
et al. should be used. Journal names should be abbreviated according to the List of Serial Title Word Abbreviations (available
from the International Serials Data System, 20 Rue Bachaumont, 75002 Paris, France; ISBN 2-904938-02-8). References should be listed
alphabetically. Citations of the literature in the list of references should include the full title of the article referred to. Personal
communications and unpublished data should not appear in the list of references.
Sample references:
Periodicals:
Buijs,
J., Egberts, M.E.W.C., Nijkamp. F.P., 1995. Toxocara canis-induced airway eosinophilia and tracheal hyporeactivity in guinea
pigs and mice, Eur. J. Pharmacol. Environ. Toxicol. Pharmacol. Sect. 293, 207.
(a) Either the original drawings plus 3 good photographs, 4 good photographs of the drawings
(on glossy paper and unmounted) or 4 high-quality computer printouts should be submitted. lllustrations may be submitted in electronic
format as well, but must always be accompanied by reproducible paper printouts. Photocopies may not be used. The photographs
should be of adequate definition and contrast. The number of illustrations should be limited to the essential.
(b) It is important
to allow for reduction to fit a single column, 8.4 cm wide, or at most a double column, maximally 17.6 cm wide. Illustrations, especially
photomicrographs, should be submitted in their final size (single or double column). When possible, all key symbols should be explained
in the figures. The following symbols can be typeset and explained (as well as all lettering) in the legends:
All letters and numerals appearing in a particular illustration should be of the same size (approximately 1.4-2 mm height when reduced
to 8.4 cm width).
(c) Graphs should be prepared so that the dark, cross-hatched background is eliminated, the faint portions of the
graphs intensified, and a sharp print obtained. This process may be avoided by using blue-ruled instead of black-ruled recording paper
for the originals.
(d) Drawings of complicated chemical structures should be prepared in the same way as graphs.
(e) A calibration
bar should be drawn on the micrographs instead of giving a magnification rate in the figure legend.
(d) All illustrations should
be referred to as figures and numbered in Arabic numerals (Fig. 1, 2 etc.).
(g) Legends to figures should make these comprehensible
without reference to the text.
(h) Tables should be numbered separately in Arabic numerals (Table 1, 2 etc.).
(i) Colour reproduction
of illustrations is available at cost. Original high-quality illustrations (preferably slides) should be well protected against possible
damage during shipment. Detailed information regarding the use of colour may be obtained from the publisher, at the time of submission
of the manuscript to the editors.
12. Proofs
One set of galley proofs will be sent to the editor named on the title page
(see 2.) Proofs will usually be set on lower quality paper. Only printer's errors may be corrected: no changes in, or additions to,
the edited manuscript will be allowed. Proofs should be returned within 48 hours to Elsevier Ireland Ltd., Elsevier House, Brookvale
Plaza, East Park, Shannon, Co. Clare, Ireland, preferably by Fax (+353 61 109107). If this period is exceeded no reminders will be sent,
the proof will be assumed to be error-free and printed without the author's corrections.
13. Page charges and reprints
There will be no page charge. 25 free reprints are provided to the corresponding author of each article. Authors will receive a reprint
order form with the acknowledgement of receipt and the copyright transfer form from the publisher: this order from should be mailed to
the publisher by return post. Reprints ordered after the journal has been printed will cost considerably more than those ordered
immediately.
14. US National Institutes of Health (NIH) voluntary posting (" Public Access") policy.
Elsevier facilitates
author response to the NIH voluntary posting request (referred to as the NIH "Public Access Policy"; see http://www.nih.gov/about/publicaccess/index.htm) by posting the peer-reviewed author's manuscript directly to PubMed Central on request from the
author, 12 months after formal publication. Upon notification from Elsevier of acceptance, we will ask you to confirm via e-mail (by
e-mailing us at NIHauthorrequest@elsevier.com ) that your work has received NIH funding and that you intend to respond
to the NIH policy request, along with your NIH award number to facilitate processing. Upon such confirmation, Elsevier will submit to
PubMed Central on your behalf a version of your manuscript that will include peer-review comments, for posting 12 months after formal
publication. This will ensure that you will have responded fully to the NIH request policy. There will be no need for you to post your
manuscript directly with PubMed Central, and any such posting is prohibited.
15. Publication information
Environmental
Toxicology and Pharmacology(ISSN 1382-6689). For 2006, Volumes 21-22 are scheduled for publication. Subscription, prices are available
upon request from the Publisher or from the Regional Sales Of?ce nearest you or from this journal's website (http://www.elsevier.com/locate/etap).
Further information is available on this journal and other Elsevier products through Elsevier's website: (http://www.elsevier.com). Subscriptions
are accepted on a prepaid basis only and are entered on a calendar year basis. Issues are sent by standard mail (surface within Europe,
air delivery outside Europe). Priority rates are available upon request. Claims for missing issues should be made within six months of
the date of dispatch.
Orders, claims and product enquiries: please contact the Customer Support Department at the Regional
Sales Office nearest you:
Orlando: Customer Service Department, 6277 Sea Harbor Drive
Orlando, FL 32887-4800, USA; Tel: +1
877 839 7126 (Toll-free number) for US Customers, Tel: +1 407 345 4020 for Customers outside US, Fax: +1 407 363 1354, e-mail: usjcs@elsevier.com
Amsterdam: Elsevier, PO Box 211, 1000 AE Amsterdam, The Netherlands; phone: (+31) 20 4853757: fax: (+31) 20 4853432: e-mail: nlinfof@elsevier.nl
Rio de Janeiro: Elsevier, Rua Sete de Setembro 111/16 Andar, 20050-002 Centro, Rio de Janeiro-RJ, Brazil; phone: (+55) (21) 509
5340; fax: (+55) (21) 507 1991; e-mail: elsevier@camputcom.br [Note (Latin America): for orders, claims and help desk
information, please contact the Regional Sales Office in New York as listed above.
Contact details for questions arising after acceptance of an article, especially those relating to proofs, are provided when an
article is accepted for publication.
16. Advertising information
Advertising orders and enquiries may be sent to: International:
Elsevier, Advertising Department, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, UK. Tel.: (+44) (0) 1865 843565: Fax: (+44)
(0) 1865 843976. U.S.A. and Canada: Elsevier Inc., Mr. Tino DeCarlo, 360 Park Avenue South, New York, NY 10010-1710
, USA;
Tel: + 1(212) 633 3815; Fax: + 1 (212) 633 3820. Japan: Elsevier Japan, Marketing Services, 1-9-15 Higashi-Azabu, Minato-ku,
Tokyo 106, Japan. Tel.: (+81) 3-5561-5033: Fax: (+81) 3-5561-5047.
All letters and numerals appearing in a particular illustration should be of the same size (approximately 1.4-2 mm height when reduced
to 8.4 cm width).
